Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise one or more of a pDC modulating cannabinoid or terpene, a monocyte modulating cannabinoid or terpene, a T-cell modulating cannabinoid or terpene, and optionally, a lymphopenia-reducing lymphopenia cannabinoid. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of a patient who has, or is at risk of developing, CRS, CSS, MAS, hyperinflammation, chronic inflammation, or a proinflammatory immune response. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of ulcers, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and the human immunodeficiency virus-associated neurocognitive disorder (HAND).
